|Bid||262.00 x 100000|
|Ask||265.20 x 100000|
|Day's Range||257.60 - 263.30|
|52 Week Range||188.04 - 311.50|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2023 - Aug 07, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GOV.SGLearn more
Savvy investors will always be looking to pick up shares of undervalued stocks. That is, after all, the essence behind the slogan ‘buy low, sell high.’ The problem, though, lies in determining which stocks are merely temporarily languishing in the doldrums and are primed to pick up steam, rather than indicating that their depressed prices are just not worth the time of day. Of course, there are many ways to assess that scenario, and one simple strategy is to examine the actions taken by insiders
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
HAE vs. PODD: Which Stock Is the Better Value Option?
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Finch Therapeutics forges a path forward, Insulet shakes up its C-suite, plus other biotech news in the Petri Dish.
Franklin Electric, Insulet and Wingstop are part of the Zacks Screen of the Week article.
Medical device company Insulet Corp produces a unique alternative to traditional insulin delivery methods. It's done through a wearable, tubeless, waterproof insulin pump called a Pod. Let's check out the charts and indicators.
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.
AMD and a new member of the S&P 500 lead this weekend's watch list of stocks that are riding positive trends, despite the tough economy.
Diabetes stock Insulet makes highly popular insulin-delivery systems. PODD stock hit new highs in March when it joined the S&P 500 index. Now, shares are breaking out of a six-week consolidation pattern, tagging all-time highs.
Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.
Insulet (PODD) delivered earnings and revenue surprises of 155.56% and 8.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ACTON, Mass., May 04, 2023--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its new organizational structure designed to accelerate innovation and commercialization. The new structure will be implemented during the second half of this year with new leadership roles effective July 1, 2023. The leadership team will continue to report to Jim Hollingshead, President and Chief Execu
ACTON, Mass., May 04, 2023--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2023.
We have narrowed our search to five stocks that are set to report earnings results this week. These are: PODD, BKNG, BILL, JCI and COLD.
ACTON, Mass., May 02, 2023--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today released its 2022 Sustainability Report highlighting accomplishments in environmental, social, and governance (ESG) across its global markets. The report details the Company’s efforts to optimize value while revolutionizing health outcomes and driving a sustainable future.
BellRing Brands (BRBR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.